Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Anixa Biosciences, Inc. ("Anixa" or the "Company") , a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, was featured ...

Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately ...

Researchers at Fred Hutch and MD Anderson discovered RNA Polymerase II on histone genes as a biomarker for cancer ...

Risk factors for secondary skin cancer after blood or marrow transplant include those who had treatment with a monoclonal ...

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

A follow-up of the ShortHER trial suggests tumor-infiltrating lymphocytes (TILs) can help identify patients who may benefit ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Fennel seeds contain anethole, a compound that has been found to exhibit anti-cancer properties by inhibiting cancer cell ...